Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

TauRx raises $31.5mm in first tranche of $111.8mm venture financing; received all

Executive Summary

Malaysian investment firm Genting Berhad’s Genting Management (Singapore) Pte. Ltd. has invested $31.5mm in TauRx Pharmaceuticals Ltd. (therapeutics and diagnostics for neurodegenerative diseases)--for a 5.6% stake--in the first tranche of a financing that could total $111.8mm, eventually providing Genting with a 20% holding to become the largest shareholder. The second tranche is expected by year end. Executives from Genting Berhad joined the company’s board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies